AML score that combines genetic and epigenetic changes might help guide therapy

Currently, doctors use chromosome markers and gene mutations to determine the best treatment for patients with acute myeloid leukemia. But a new study suggests that a score based on seven mutated genes and the epigenetic changes that the researchers discovered were also present might help guide treatment by identifying novel subsets of patients. Patients with a low score had the best outcomes, and those with high scores had the poorest outcomes. Read more